Supernus Pharmaceuticals (NASDAQ:SUPN) Releases Quarterly Earnings Results, Misses Estimates By $1.43 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43), FiscalAI reports. The business had revenue of $201.90 million during the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 13.07% and a negative net margin of 3.74%.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $44.63 on Monday. The business has a 50 day simple moving average of $46.27 and a two-hundred day simple moving average of $49.08. Supernus Pharmaceuticals has a 1-year low of $32.83 and a 1-year high of $59.68. The stock has a market capitalization of $2.59 billion, a PE ratio of -87.51, a P/E/G ratio of 0.95 and a beta of 0.56.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on SUPN shares. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $62.83.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $21,908,000. Woodline Partners LP increased its stake in Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares during the period. Bank of America Corp DE boosted its position in Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after buying an additional 338,584 shares during the period. Morgan Stanley grew its stake in Supernus Pharmaceuticals by 42.9% in the 4th quarter. Morgan Stanley now owns 1,079,471 shares of the specialty pharmaceutical company’s stock worth $53,650,000 after acquiring an additional 324,154 shares in the last quarter. Finally, UBS Group AG increased its position in shares of Supernus Pharmaceuticals by 137.6% during the third quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock worth $25,812,000 after acquiring an additional 312,775 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.